Shelton Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $449K | Sell |
3,572
-64
| -2% | -$8.04K | 0.01% | 362 |
|
|
2025
Q1 | $402K | Sell |
3,636
-175
| -5% | -$19.4K | 0.01% | 375 |
|
|
2024
Q4 | $520K | Sell |
3,811
-167
| -4% | -$22.8K | 0.01% | 337 |
|
|
2024
Q3 | $458K | Sell |
3,978
-76
| -2% | -$8.76K | 0.01% | 368 |
|
|
2024
Q2 | $558K | Sell |
4,054
-96
| -2% | -$13.2K | 0.02% | 315 |
|
|
2024
Q1 | $572K | Sell |
4,150
-125
| -3% | -$17.2K | 0.02% | 325 |
|
|
2023
Q4 | $563K | Sell |
4,275
-241
| -5% | -$31.8K | 0.02% | 316 |
|
|
2023
Q3 | $508K | Sell |
4,516
-245
| -5% | -$27.6K | 0.02% | 316 |
|
|
2023
Q2 | $449K | Sell |
4,761
-136
| -3% | -$12.8K | 0.02% | 336 |
|
|
2023
Q1 | $496K | Hold |
4,897
| – | – | 0.02% | 300 |
|
|
2022
Q4 | $585K | Sell |
4,897
-119
| -2% | -$14.2K | 0.06% | 252 |
|
|
2022
Q3 | $533K | Hold |
5,016
| – | – | 0.03% | 298 |
|
|
2022
Q2 | $489K | Hold |
5,016
| – | – | 0.02% | 322 |
|
|
2022
Q1 | $470K | Hold |
5,016
| – | – | 0.02% | 364 |
|
|
2021
Q4 | $427K | Sell |
5,016
-192
| -4% | -$16.3K | 0.02% | 415 |
|
|
2021
Q3 | $499K | Hold |
5,208
| – | – | 0.02% | 355 |
|
|
2021
Q2 | $507K | Buy |
+5,208
| New | +$507K | 0.02% | 372 |
|